Rekombinanter Osteocalcin Antikörper

Produktnummer ABIN7881889

Der Kaninchen Monoklonal anti-Osteocalcin Antikörper wird verwendet zum Nachweis von Osteocalcin in Proben von Human. Er wurde validiert für WB.

Kurzübersicht für Rekombinanter Osteocalcin Antikörper (ABIN7881889)

Target: Osteocalcin (BGLAP)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser Osteocalcin Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Klon: 32B73

Produktdetails anti-Osteocalcin Antikörper

Verwendungszweck: BGLAP Antibody / Osteocalcin

Aufreinigung: Affinity-chromatography

Immunogen: A synthesized peptide derived from human Osteocalcin was used as the immunogen for the BGLAP antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the BGLAP antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store the BGLAP antibody at -20oC.

Details zu Osteocalcin

Target: Osteocalcin (BGLAP)

Andere Bezeichnung: BGLAP

Hintergrund: BGLAP antibody detects bone gamma carboxyglutamate protein, also known as osteocalcin, encoded by the BGLAP gene. Other identifiers include Bone Gla protein, BGP, and OC. Osteocalcin is a small, secreted non collagenous protein of bone produced exclusively by osteoblasts. It binds calcium and hydroxyapatite in bone matrix, contributing to bone mineralization and remodeling. Because of its specificity to bone forming cells, osteocalcin is widely used as a marker of osteoblast activity and bone turnover.

BGLAP antibody is widely applied in skeletal biology, endocrinology, and metabolic disease research. Osteocalcin not only functions in bone formation but also acts as a hormone influencing glucose metabolism, insulin sensitivity, and energy expenditure. By detecting BGLAP, researchers can study the dual role of osteocalcin as both a structural bone protein and an endocrine regulator. Circulating osteocalcin levels serve as clinical biomarkers of bone turnover in osteoporosis, fracture healing, and metabolic disorders.

Applications of BGLAP antibody include western blotting, immunohistochemistry, and ELISA. Western blotting identifies osteocalcin in osteoblast cultures and bone extracts, immunohistochemistry localizes expression in bone tissue sections, and ELISA quantifies circulating osteocalcin in serum or plasma. These complementary approaches provide powerful methods to link bone metabolism with systemic physiology.

Research has shown that osteocalcin influences insulin secretion from pancreatic beta cells and testosterone synthesis in Leydig cells, placing bone as an active regulator of endocrine function. Altered osteocalcin expression or signaling is linked to type 2 diabetes, obesity, and reproductive disorders. By applying BGLAP antibody, scientists can evaluate how bone derived signals integrate into whole body metabolic control.

In oncology, osteocalcin expression has been observed in certain cancers, including prostate and lung tumors that metastasize to bone. Detection of osteocalcin with antibody based methods provides insights into tumor bone interactions and metastatic microenvironments. This broadens the relevance of BGLAP antibody beyond traditional bone research.

BGLAP antibody from NSJ Bioreagents provides strong specificity for osteocalcin, ensuring reliable detection in skeletal, metabolic, and cancer biology research.

UniProt: P02818